202 related articles for article (PubMed ID: 27693635)
1. Immunological, anti-angiogenic and clinical effects of intratumoral interleukin 12 electrogene therapy combined with metronomic cyclophosphamide in dogs with spontaneous cancer: A pilot study.
Cicchelero L; Denies S; Vanderperren K; Stock E; Van Brantegem L; de Rooster H; Sanders NN
Cancer Lett; 2017 Aug; 400():205-218. PubMed ID: 27693635
[TBL] [Abstract][Full Text] [Related]
2. Intratumoural interleukin 12 gene therapy stimulates the immune system and decreases angiogenesis in dogs with spontaneous cancer.
Cicchelero L; Denies S; Haers H; Vanderperren K; Stock E; Van Brantegem L; de Rooster H; Sanders NN
Vet Comp Oncol; 2017 Dec; 15(4):1187-1205. PubMed ID: 27506827
[TBL] [Abstract][Full Text] [Related]
3. Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients.
Denies S; Cicchelero L; de Rooster H; Daminet S; Polis I; Van de Maele I; Sanders NN
Vet Comp Oncol; 2017 Jun; 15(2):594-605. PubMed ID: 26961119
[TBL] [Abstract][Full Text] [Related]
4. Combination of interleukin-12 gene therapy, metronomic cyclophosphamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication.
Denies S; Cicchelero L; Van Audenhove I; Sanders NN
J Control Release; 2014 Aug; 187():175-82. PubMed ID: 24887014
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.
Mitchell L; Thamm DH; Biller BJ
J Vet Intern Med; 2012; 26(2):355-62. PubMed ID: 22303814
[TBL] [Abstract][Full Text] [Related]
6. Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs.
Rasmussen RM; Kurzman ID; Biller BJ; Guth A; Vail DM
Vet Comp Oncol; 2017 Jun; 15(2):421-430. PubMed ID: 26522053
[TBL] [Abstract][Full Text] [Related]
7. Toxicity of metronomic cyclophosphamide chemotherapy in a UK population of cancer-bearing dogs: a retrospective study.
Harper A; Blackwood L
J Small Anim Pract; 2017 Apr; 58(4):227-230. PubMed ID: 28133740
[TBL] [Abstract][Full Text] [Related]
8. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
Jordan M; Waxman DJ
Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
[TBL] [Abstract][Full Text] [Related]
9. Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma.
Burton JH; Mitchell L; Thamm DH; Dow SW; Biller BJ
J Vet Intern Med; 2011; 25(4):920-6. PubMed ID: 21736624
[TBL] [Abstract][Full Text] [Related]
10. Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model.
Chuang TF; Lee SC; Liao KW; Hsiao YW; Lo CH; Chiang BL; Lin XZ; Tao MH; Chu RM
Int J Cancer; 2009 Aug; 125(3):698-707. PubMed ID: 19431145
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of toxicities from combined metronomic and maximal-tolerated dose chemotherapy in dogs with osteosarcoma.
Bracha S; Walshaw R; Danton T; Holland S; Ruaux C; Obradovich J
J Small Anim Pract; 2014 Jul; 55(7):369-74. PubMed ID: 24803081
[TBL] [Abstract][Full Text] [Related]
12. Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model.
Son CH; Shin DY; Kim SD; Park HS; Jung MH; Bae JH; Kang CD; Yang K; Park YS
J Immunother; 2012 Oct; 35(8):607-14. PubMed ID: 22996366
[TBL] [Abstract][Full Text] [Related]
13. Cancer electrogene therapy with interleukin-12.
Cemazar M; Jarm T; Sersa G
Curr Gene Ther; 2010 Aug; 10(4):300-11. PubMed ID: 20560875
[TBL] [Abstract][Full Text] [Related]
14. Metastasized Leydig cell tumor in a dog.
Togni A; Rütten M; Bley CR; Hurter K
Schweiz Arch Tierheilkd; 2015 Feb; 157(2):111-5. PubMed ID: 26753337
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.
Hermans IF; Chong TW; Palmowski MJ; Harris AL; Cerundolo V
Cancer Res; 2003 Dec; 63(23):8408-13. PubMed ID: 14679003
[TBL] [Abstract][Full Text] [Related]
16. Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy.
Lansiaux A; Salingue S; Dewitte A; Clisant S; Penel N
Invest New Drugs; 2012 Feb; 30(1):403-4. PubMed ID: 20449626
[TBL] [Abstract][Full Text] [Related]
17. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome.
Ge Y; Domschke C; Stoiber N; Schott S; Heil J; Rom J; Blumenstein M; Thum J; Sohn C; Schneeweiss A; Beckhove P; Schuetz F
Cancer Immunol Immunother; 2012 Mar; 61(3):353-62. PubMed ID: 21915801
[TBL] [Abstract][Full Text] [Related]
18. Immunologic Effects of Stereotactic Body Radiotherapy in Dogs with Spontaneous Tumors and the Impact of Intratumoral OX40/TLR Agonist Immunotherapy.
Boss MK; Watts R; Harrison LG; Hopkins S; Chow L; Trageser E; Easton C; LaRue SM; Regan D; Dewhirst MW; Dow S
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055015
[TBL] [Abstract][Full Text] [Related]
19. iNOS expression in CD4+ T cells limits Treg induction by repressing TGFβ1: combined iNOS inhibition and Treg depletion unmask endogenous antitumor immunity.
Jayaraman P; Alfarano MG; Svider PF; Parikh F; Lu G; Kidwai S; Xiong H; Sikora AG
Clin Cancer Res; 2014 Dec; 20(24):6439-51. PubMed ID: 25278453
[TBL] [Abstract][Full Text] [Related]
20. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.
Tongu M; Harashima N; Monma H; Inao T; Yamada T; Kawauchi H; Harada M
Cancer Immunol Immunother; 2013 Feb; 62(2):383-91. PubMed ID: 22926062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
